EXoZymes Inc is focused on using a biomanufacturing platform to create valuable biochemicals, including Active Pharmaceutical Ingredients or APIs, biofuels, food flavors, and cosmetics, offering a sustainable alternative to traditional chemical production methods... Show more
A.I.dvisor tells us that EXOZ and CTNM have been poorly correlated (+24% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that EXOZ and CTNM's prices will move in lockstep.
| Ticker / NAME | Correlation To EXOZ | 1D Price Change % | ||
|---|---|---|---|---|
| EXOZ | 100% | +1.24% | ||
| CTNM - EXOZ | 24% Poorly correlated | +1.99% | ||
| ALLR - EXOZ | 21% Poorly correlated | +2.76% | ||
| EDVA - EXOZ | 21% Poorly correlated | +2.06% | ||
| ORIC - EXOZ | 21% Poorly correlated | +1.01% | ||
| MENS - EXOZ | 10% Poorly correlated | -2.79% | ||
More | ||||
Industry Biotechnology
The Stochastic Oscillator for EXOZ moved out of overbought territory on November 06, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 12 similar instances where the indicator exited the overbought zone. In 11 of the 12 cases the stock moved lower. This puts the odds of a downward move at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EXOZ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
EXOZ broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for EXOZ entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where EXOZ's RSI Oscillator exited the oversold zone, 13 of 14 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Momentum Indicator moved above the 0 level on October 29, 2026. You may want to consider a long position or call options on EXOZ as a result. In 26 of 30 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 87%.
The Moving Average Convergence Divergence (MACD) for EXOZ just turned positive on October 29, 2026. Looking at past instances where EXOZ's MACD turned positive, the stock continued to rise in 8 of 9 cases over the following month. The odds of a continued upward trend are 89%.
Following a +15.01% 3-day Advance, the price is estimated to grow further. Considering data from situations where EXOZ advanced for three days, in 79 of 88 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
The Tickeron PE Growth Rating for this company is 20 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 77 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (10.947) is normal, around the industry mean (3.498). P/E Ratio (-3.592) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 86 (best 1 - 100 worst), indicating slightly worse than average price growth. EXOZ’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EXOZ’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.